Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA158433 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:B cell depletion therapy is efficacious in RA patients failing on TNF blocking agents. However, approximately 40-50% of the rituximab-treated RA patients have a poor response. We investigated wheter baseline gene expression levels can discriminate between clinical nonresponders and responders to rituximab Whole blood total RNA is isolated from PAXgene tubes obtained prior to start of rituximab treatment
2012-04-09 | E-GEOD-37107 | biostudies-arrayexpress
Project description:New and effective therapeutical options are available for the treatment of Rheumatoid Arthritis. One of such treatments is rituximab, and chimeric anti-CD20 antibody that selectively depletes the CD20+ B cell subpopulation. Similar to established anti-TNF alpha therapies, there is a subgroup of RA patients that do not experience significant clinical response. Therefore, one of the major necessities in actual RA therapeutical management is to identify reliable predictors of the response to this therapies. In the present study we have evaluated 3 blood cell types (i.e. whole blood, isolated B cells and isolated CD4 T cells) using microarray gene expression profiling to identify their potential use as biomarkers for rituximab response. In all three tissues evaluated, we have identified statistically significant differentially expressed genes. The most relevant candidates have been reevaluated using RealTime PCR. These genes were: TRAF1 and arginase 1 in whole blood, Toll-Like Receptor 4 (TLR4) in CD4+ T cells and AT-rich interactive domain 3A (ARID3A) in B cells. In the present study we have demonstrated the potential of different blood cell types for the prediction of the response to rituximab. In particular, we have found a set of relevant candidate genes that could be the basis for future treatment response prediction.
2009-10-02 | GSE15316 | GEO
Project description:Objective: We performed whole-blood transcriptomic profiling for patients with rheumatoid arthritis (RA) who received rituximab (RTX). We aimed to identify a molecular signature that could predict the clinical response to RTX and transcriptomic changes after RTX therapy.
2015-01-01 | GSE54629 | GEO
Project description:Transcription profiling of plasma cells and plasmablasts from patients with primary immune thrombocytopenia after rituximab treatment compared to treatment nave patients or healthy donors
2025-01-22 | E-MEXP-3711 | ExpressionAtlas
Project description:Objective: We performed whole-blood transcriptomic profiling for patients with rheumatoid arthritis (RA) who received rituximab (RTX). We aimed to identify a molecular signature that could predict the clinical response to RTX and transcriptomic changes after RTX therapy. Methods: We performed a microarray assay of the whole human genome with RNA from a peripheral blood sample taken before the first RTX cycle from 68 patients included in the SMART study (24 EULAR non-responders and 44 responders at week 24). The transcriptomic profile was also assessed 24 weeks after the first RTX administration
2015-01-01 | E-GEOD-54629 | biostudies-arrayexpress
Project description:Whole-blood transcriptomic profiling highlights rituximab response in rheumatoid arthritis
| PRJNA237237 | ENA
Project description:Transcriptional profiling of blood exposure response gene signature across clinical studies on The Tobacco Heating System 2.2 (THS 2.2) dataset 1
2025-01-23 | E-MTAB-6558 | ExpressionAtlas
Project description:Transcriptional profiling of blood exposure response gene signature across clinical studies on The Tobacco Heating System 2.2 (THS 2.2) dataset 2
2025-01-23 | E-MTAB-6559 | ExpressionAtlas
Project description:Endogenous or iatrogenic antitumor immune responses can improve the course of follicular lymphoma (FL), but may be diminished by immunoregulatory mechanisms in the tumor microenvironment. These may include effects of programmed death (PD)-1, a coinhibitory receptor that impairs T-cell function and is highly expressed on intratumoral T cells. In a Phase II trial, we tested the efficacy of pidilizumab, a humanized anti-PD-1 monoclonal antibody, with rituximab in patients with rituximab-sensitive FL relapsed after 1-4 prior therapies. Pidilizumab was administered at 3 mg/kg every 4 weeks for 4 infusions, plus 8 optional infusions every 4 weeks for patients with stable disease or better. Starting 2 weeks after the first infusion of pidilizumab, rituximab was given at 375 mg/m2 weekly for 4 weeks. Peripheral blood and tumor biopsies were studied to assess immunological effects of pidilizumab. The combination was well-tolerated, with no grade 3/4 toxicities. Overall (66%) and complete (52%) response rates in 29 evaluable patients were high, with tumor regression in 86% of patients. Median progression-free survival was 18.8 months, and was not reached for the 19 responders. Peripheral blood immunophenotyping showed increased memory CD4+ T cells and activation of NK cells after pidilizumab therapy. Tumor response and progression-free survival were associated with T-cell activation gene signatures in tumor gene expression profiling data, both at baseline and in changes induced by pidilizumab. The efficacy of pidilizumab with rituximab compared favorably to historical retreatment with rituximab monotherapy in patients with relapsed FL. Pidilizumab may benefit patients with pre-existing endogenous antitumor immune responses. This set contains 26 samples in total. 8 pairs of pre- and post-treatment samples, and 10 additional pre-treatment samples.
2013-11-21 | E-GEOD-52562 | biostudies-arrayexpress
Project description:Transcription profiling human whole blood from children with pre-type1diabetes
2025-01-16 | E-TABM-666 | ExpressionAtlas